3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Urinary Bladder Neoplasms
10
Pancreatic Neoplasms
7
Carcinoma, Merkel Cell
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Renal Cell
4
Recurrence
3
Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Cancer Resectable
1
Non-Muscle Invasive Bladder Neoplasms
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Microsatellite Instability
1
Interventions
pembrolizumab
3
Carboplatin
3
Nivolumab
2
Injections
2
Docetaxel
2
Cisplatin
2
BMS-753493
2
zimberelimab
1
urelumab
1
tislelizumab
1
tesetaxel
1
spartalizumab
1
olaparib
1
liposomal doxorubicin
1
linifanib
1
lenvatinib
1
ixabepilone
1
durvalumab
1
avelumab
1
avdoralimab
1
adavosertib
1
TAS-119
1
Rifampin
1
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
1
Maximum Tolerated Dose
1
Linoleic Acids, Conjugated
1
Lapatinib
1
Itraconazole
1
Irinotecan
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Advanced Solid Tumors
×
avelumab
×
Clear all
NCT02994953
2024-09-20
COMBO
EMD Serono
Phase 1
Terminated
52 enrolled
34 charts